AstraZeneca has closed a $2 billion strategic equity investment in U.S. cancer drug developer Summit Therapeutics, acquiring roughly 12% of the company. Summit announced the closing on October 5, with the funds earmarked to accelerate development of its investigational bispecific antibody ivonescimab. CEO Pascal Soriot has signaled that the drug could anchor a next generation of cancer combination therapies — a rare big bet for a company that has long insisted it can hit its targets without M&A.
The terms are straightforward: AstraZeneca purchased about 108,955 shares of Summit preferred stock, convertible into common shares at a 1-to-1,000 ratio. The investment implies a common-share price of $18.36 — a premium over Summit's closing price on the day the deal was announced. Summit shares rallied nearly 18% in after-hours trading in New York after the announcement.
This isn't AstraZeneca's first pass at the company: takeover rumors circulated last July. A strategic equity stake gives the pharma giant exposure to Summit's pipeline without an outright acquisition.
Ivonescimab is what the money is really about: a PD-1/VEGF bispecific antibody that packs immune checkpoint therapy and anti-angiogenesis activity into a single molecule, described by Summit as a potential first-in-class drug. It was engineered by China's Akeso Inc., which licensed it to Summit for North and South America, Europe, the Middle East, Africa, and Japan under an agreement worth up to $5 billion.
The deal includes a clinical collaboration: ivonescimab will be tested in combination with AstraZeneca's experimental antibody-drug conjugate sonesitatug vedotin (Sone-Ve), starting with gastrointestinal cancers. Summit also plans combinations with ADCs including Datroway (datopotamab deruxtecan) across multiple solid tumor settings.
"This investment reflects AstraZeneca's confidence in Summit and in ivonescimab's potential to redefine cancer treatment," said Summit Chairman and co-CEO Robert W. Duggan.
AstraZeneca has set a target of $80 billion in annual revenue by 2030. But three of its biggest cancer drugs are set to lose patent protection in the early 2030s, and the company needs new growth engines. Soriot said in July that AstraZeneca did not "need M&A to deliver" its target, denied reports of a $400 billion Bristol Myers Squibb megadeal, and stressed the focus was on small, early acquisitions "to build value along the way" — the Summit stake fits that playbook.
The money is in the bank; the hard part comes next. The bispecific-plus-ADC combinations must deliver convincing data across solid tumors to live up to the "next generation" billing. The brutal reality of oncology R&D is that early stories are always the most compelling — the late-stage trials are where they get tested. Whether ivonescimab earns the promise both companies are making will be decided in the clinic.